Prostate Studies
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Comprehensive Genetic Characterization of Intraprostatic Chronic Inflammation and Prostate Cancer in
African American Men


ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
More Information

Taste in Prostate Cancer

A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic
Men with Castration Resistant Metastatic Prostate Cancer: The TRANSFORMER Trial
More Information

A Phase II, Randomized, Open-Label, Multicenter Study in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Who Have PRIMary Resistance to Abiraterone Acetate or Enzalutamide Treatment Comparing the Anit-Tumor Effect of CABazitaxel to Alternative Androgen Receptors (AR) Targeted Therapy
More Information

A Phase II Open-Label, Parallel Group Study of Abiraterone Acetate Plus Prednisone in African-American and Caucasian Men with Metastatic Castration-Resistant Prostate Cancer
More Information

Alliance A031201
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
More Information

GU 115
A Double-Blinded, Placebo-Controlled, Randomized Phase II Trial of Enzalutamide With or Without the PI3 Kinase/m TOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

More Information

UAB 1336
A Phase 2 Trial of Carfilzomib for Metastatic Castration-Resistant Prostate Cancer Following Chemotherapy and Androgen Pathway Inhibitors
More Information

A Phase I Study of a Prostate-Specific Membrane Antigen Targeting-Tubulysin Conjugate EC1169 in Patients With Recurrent Metastatic, Castration-Resistant Prostate Cancer (mCRPC)
More Information

Radium-223 Alpha Emitter Agent in Safety Study in mCRPC Population for Long-Term Evaluation
More Information

Sotio SP005
A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
More Information


A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer (PREDICT)
More Information

BAY 16544

A Randomized Open-label Phase IIa Study Evaluating the Efficacy and Safety of Radium-223 Dichloride in Combination with Abiraterone Acetate or Enzalutamide in Subjects with CRPC Who Have Bone Metastases
More Information

RTOG 0815
A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer
More Information

RTOG 0924
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy In Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
More Information

TUHC 07/25/13 - Genetics of Prostate Cancer

BAY 15396

A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC)
More Information

SWOG S1216

A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
More Information

1430 Tulane Ave, New Orleans, LA 70112 504-988-8070